(Total Views: 696)
Posted On: 02/12/2024 10:18:08 AM
Post# of 155142
haven't been on in a while, hope everyone is well. yes, I'll take $1 at this point!
here's the issue - there are 2 things needed for a $3 SP (which equates to billions in market value) - first, we have to execute, but second, and here's the kicker - the market has to assign a value to that execution. the sugar rush days of 2020 / 2021 are long gone, and won't be back for 10 years at least (it was an epic bubble for speculative stocks). that's why developments that seem significant now draw a collective yawn from the market place.
i am in 3 biotechs now, having diversified over the past couple years. I won't go into details on them - but they are further down the path than CytoDyn _ one is generating revenue and the other has a 60% phase III readout this Fall - yet both have really small valuations still.
My point is that we're in a different market environment now for these early stage biotechs - and after the collapse of Silicon Valley Bank (biggest lender to pre-revenue biotechs) as well as the general malaise in the biotech space, the bar for results is much higher. CytoDyn is not alone, there are tons of companies in the same boat.
I think Jay Lalezari is great, and will do a very good job for us - but i've adjusted my expectations as to when we'll see a recovery. My gut is that it will only follow results and will be tied to showing that we're close to generating revenue.
here's the issue - there are 2 things needed for a $3 SP (which equates to billions in market value) - first, we have to execute, but second, and here's the kicker - the market has to assign a value to that execution. the sugar rush days of 2020 / 2021 are long gone, and won't be back for 10 years at least (it was an epic bubble for speculative stocks). that's why developments that seem significant now draw a collective yawn from the market place.
i am in 3 biotechs now, having diversified over the past couple years. I won't go into details on them - but they are further down the path than CytoDyn _ one is generating revenue and the other has a 60% phase III readout this Fall - yet both have really small valuations still.
My point is that we're in a different market environment now for these early stage biotechs - and after the collapse of Silicon Valley Bank (biggest lender to pre-revenue biotechs) as well as the general malaise in the biotech space, the bar for results is much higher. CytoDyn is not alone, there are tons of companies in the same boat.
I think Jay Lalezari is great, and will do a very good job for us - but i've adjusted my expectations as to when we'll see a recovery. My gut is that it will only follow results and will be tied to showing that we're close to generating revenue.
(7)
(6)
